v3.26.1
Consolidated Statement of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Cash flows from operating activities:    
Net loss from continuing operations $ (6,905,282) $ (10,650,464)
Loss from discontinued operations, net of tax 0 (1,152,276)
Gain on sale of discontinued operations   1,434,479
Adjustments to reconcile net loss to net cash used in operating activities:    
Gain on sale of discontinued operations   (1,434,479)
Stock-based compensation 692,790 827,043
Depreciation and amortization of intangible assets 78,675 83,486
Amortization of right of use assets 136,379 113,774
Change in fair value of earnout liabilities (149,584) 0
Inventory write-down 60,963 0
Amortization of debt discount 0 19,549
Loss on forward purchase agreement 0 5,700,451
Changes in operating assets and liabilities:    
Accounts receivable and other current assets 44,151 (4,096)
Inventory 370,853 (108,705)
Prepaid expenses 537,685 959,501
Income taxes receivable 301,838 (97,279)
Assets available for sale   4,662,980
Accounts payable 126,858 (359,143)
Accrued expenses and other liabilities 1,515,945 (1,281,721)
Lease liability (140,537) (117,013)
Liabilities available for sale   (2,489,343)
Net cash used in operating activities (3,329,266) (3,893,256)
Cash flows from investing activities    
Cash paid for Elevai Acquisition transaction costs (150,000)  
Purchases of property and equipment (14,225)  
Cash paid in AxoBio Disposition   (748,796)
Net cash used in investing activities (164,225) (748,796)
Cash flows from financing activities:    
Proceeds from issuance of Common Stock, net of costs 3,483,790 2,687,225
Proceeds from exercise of Common Stock warrants 1,000,000  
Repayment of loans (440,698) (714,181)
Deferred offering costs   (86,314)
Net cash provided by financing activities 4,043,092 1,886,730
Net increase (decrease) in cash and cash equivalents 549,601 (2,755,322)
Cash and cash equivalents - beginning of period 157,139 2,912,461
Cash and cash equivalents - end of period 706,740 157,139
Supplemental cash flow information:    
Interest paid 18,214 29,466
Income taxes refunded 265,576  
Non-cash financing activity:    
Fair value of shares issued in Elevai Acquisition 660,805  
Consideration payable 67,742  
Earnout liabilities in Elevai Acquisition 301,633  
Insurance premium financing agreements $ 389,479 495,692
Fair value of shares received in AxoBio Disposition   23,456,179
Net assets sold in AxoBio Disposition   21,921,697
Common Stock issued in connection with conversion of Notes   848,500
Decrease in right of use asset and lease liabilities related to termination of lease   $ 333,003